TherapeuticsMD (TXMD) Reports In-Line Q4 EPS

TherapeuticsMD (NYSE: TXMD) reported Q4 EPS of ($0.12), in-line with the analyst estimate of ($0.12). Revenue for the quarter came in at $4.49 million versus the consensus estimate of $5.91 million.

For earnings history and earnings-related data on TherapeuticsMD (TXMD) click here.

You May Also Be Interested In

• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• Primoris cuts 2026 outlook on renewables cost overruns, COO exits
• Ennis (EBF) Reports In-Line Q1 EPS